CD8A and neoplasm: Immunotherapy offers novel and potentially effective routes to treating cancer, and progress has been made with regard to adoptively transferring expanded or genetically engineered T cells back into patients.6, 7 However, the safety and efficacy of CD8+ T-cell-based therapies depend on whether the corresponding target antigens are exclusively expressed by tumour cells and not by healthy tissues, and whether they are recognised by the T-cell receptor (TCR) with sufficient affinity.